Moderna posts oncology event presentation on intismeran cancer vaccine program

Moderna

Moderna

MRNA

0.00
  • Moderna posted an oncology presentation detailing intismeran autogene, an investigational mRNA-based individualized neoantigen therapy designed to each patient’s tumor and HLA type.
  • Presentation highlighted a 5-year update from Phase 2 KEYNOTE-942 in resected melanoma using intismeran autogene with pembrolizumab.
  • Disclosed manufacturing consistency in the study: 91% of combination-arm patients received products containing 34 targetable neoantigens.
  • Reported limited commonality across patients’ targets: 99.1% of neoantigens were unique, reinforcing the therapy’s individualized design.
  • Outlined a partnered development strategy with Merck, focused first on IO-sensitive tumors, with exploratory work in less IO-responsive cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.